We are live on ! Find out more
FNCH

Finch Therapeutics Group, Inc. Common Stock
FNCH

Delisted

FNCH was delisted on the 24th of May, 2024.

Back to rankings

1 hedge funds and large institutions have $29.1K invested in Finch Therapeutics Group, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

6.7% less ownership

Funds ownership: 8.02% → 1.32% (-6.7%)

91% less funds holding

Funds holding: 11 → 1 (-10)

91% less capital invested

Capital invested by funds: $338K → $29.1K (-$309K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 10

Holders
1
Holders Change
-10
Holders Change %
-90.91%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$155K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$94.3K
3
IC
Ikarian Capital
Texas
-$18.1K
4
TRCT
Tower Research Capital (TRC)
New York
-$10.8K
5
BL
Bleichroeder LP
New York
-$2.52K

FNCH Hedge Fund Activity: Q2 2024 in Review

1 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Finch Therapeutics Group, Inc. Common Stock (FNCH) for Q2 2024, worth a combined $29.1K — down 91% from $338K a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of FNCH and 0 opened new positions — a net loss of 10 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Susquehanna International Group, exiting entirely with an estimated $155K sold.

  • 1 institutional investor held Finch Therapeutics Group, Inc. Common Stock (FNCH) as of Q2 2024, down from 11 in Q1 2024.
  • Funds reported $29.1K of Finch Therapeutics Group, Inc. Common Stock stock for Q2 2024, down 91% quarter-over-quarter.
  • 0 funds opened new Finch Therapeutics Group, Inc. Common Stock positions in Q2 2024 and 10 closed out, a net change of -10 holders.
  • The largest Finch Therapeutics Group, Inc. Common Stock seller in Q2 2024 was Susquehanna International Group, an estimated $155K sold.

Based on aggregated 13F filings for Q2 2024.